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Abstract
Background: Class II MHC molecules (MHC II) are cell surface receptors displaying short protein fragments for the
surveillance by CD4+ T cells. Antigens therefore have to be loaded onto this receptor in order to induce productive immune
responses. On the cell surface, most MHC II molecules are either occupied by ligands or their binding cleft has been blocked
by the acquisition of a non-receptive state. Direct loading with antigens, as required during peptide vaccinations, is
therefore hindered.
Principal Findings: Here we show, that the in vivo response of CD4+ T cells can be improved, when the antigens are
administered together with ‘MHC-loading enhancer’ (MLE). MLE are small catalytic compounds able to open up the MHC
binding site by triggering ligand-release and stabilizing the receptive state. Their enhancing effect on the immune response
was demonstrated here with an antigen from the influenza virus and tumour associated antigens (TAA) derived from the NY-
ESO-1 protein. The application of these antigens in combination with adamantane ethanol (AdEtOH), an MLE compound
active on human HLA-DR molecules, significantly increased the frequency of antigen-specific CD4+ T cells in mice transgenic
for the human MHC II molecule. Notably, the effect was evident only with the MLE-susceptible HLA-DR molecule and not
with murine MHC II molecules non-susceptible for the catalytic effect of the MLE.
Conclusion: MLE can specifically increase the potency of a vaccine by facilitating the efficient transfer of the antigen onto
the MHC molecule. They may therefore open a new way to improve vaccination efficacy and tumour-immunotherapy.
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Introduction
Since Edward Jenner discovered a small pox vaccine in 1789,
investigators have focused for more than 200 years on developing
strategiesto improvehumanlifebycreating vaccinesagainst various
infectious diseases. Up to now, over 20 diseases are preventable due
to successful vaccination. More recently, immunologist started to
explore the possibility to amplify patient’s immune response against
tumours using vaccination. As first ‘tumour-specific’ vaccines
‘‘Gardasil’’ (Merck) [1] and ‘‘Cervarix’’ (GlaxoSmithKline) [2]
have been introduced for prophylaxis against cervical cancer.
Analogue to ‘traditional’ vaccines, they contain viral components of
the cancer-causing human papilloma virus (HPV), whereas
treatment of most other cancers may rely on targeting self-antigens.
A promising group of these tumour-associated antigens (TAA)
includes cancer testis antigens (CT), which are expressed on various
tumourswhilebeingabsentonnormaltissueexceptforthetestis[3].
They therefore represent attractive targets for tumour-immuno-
therapy. Among those, NY-ESO-1 is one of the most prominent
and well-studied antigens [4]. Several clinical trials have been
launched to determine its efficacy [5].
Vaccination efficacy depends largely on the the immune-
modulatory capacity of the adjuvant, also known as ‘immunolo-
gist’s ‘‘dirty’’ little secret’ [6]. Innate signals being co-delivered
with the vaccine drastically influence the strength and direction of
the immune response. The importance of microbial-derived
vaccine additives, such as the TLR-agonists CpG [7] or Pam3Cys
[8,9], and the enhancing effect of cell-damage associated
compounds, namely uric acid [10] and ATP [11] has just begun
to be fully acknowledged and represents a field that is currently
under extensive investigation [12].
Another way to increase antigenicity is to improve antigen
delivery to immunogenic APC. T cell epitopes linked to antibodies
targeting DC specific surface molecules such as DC-SIGN [13] or
DEC-205 [14] have demonstrated their efficacy in various mouse
models. While these approaches require the generation of rather
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enhancer’ (MLE) may represent an elegant alternative. MLE are
small catalytic compounds that are simply added to the antigen
mixture [15–20]. The mechanism is based on the fact that on the
cell surface the efficacy of antigen loading is hindered by the lack
of empty and accessible MHC II molecules. They are either
occupied already by endogenous ligands or, upon loosing their
ligand, have acquired a non-receptive state. The latter is
characterized by the inability of an empty MHC molecule to
bind a peptide ligand, putatively caused by a conformation in
which the peptide-binding site is blocked [21]. The rapid
transformation into this non-receptive state is regarded as a
safety-mechanism, avoiding the unwanted and potential
dangerous loading and presentation of self-antigens on the surface.
We had shown earlier that small organic MLE can enhance
antigen loading by reversing the inactive state and by triggering
the release of ligands with lower affinity [16,18]. By targeting the
conserved P1-pocket located within the binding cleft of MHC II
molecules, these MLE are able to stabilize the peptide receptive
state, which allows efficient loading of APC with T cell antigens.
The interaction is highly specific. Organic MLE carrying
adamantyl groups such as adamantane ethanol (AdEtOH) are
effective only on allelic variants of HLA-DR expressing a glycin
residue at the dimorphic position b86 [18], while the allel-
specificity of catalytic amino acid derivatives (‘peptide-MLE’)
depends on their active amino acid side chain [19].
Several studies in mouse models have shown that long-term
protection requires an adequate and sustained CD4+ T cell
response, which provides help to effector cells via the production
of several cytokines [22–24]. Hence, also the T cell priming for
tumour immune responses requires peptides loaded efficiently onto
MHC II molecules. In vitro, the presence of MLE during antigen
loading increased the sensitivity of the CD4+ T cell response for a
modelantigen byuptotwo ordersofmagnitude[18].Hereweshow
that the enhancing effect is also observed in vivo. When using MLE
asan additiveduringvaccinationwithTAA,a significant increase in
the number of activated CD4+ T cells was observed.
Results
MLE facilitate antigen-loading of HLA-DR expressing
dendritic cells
In previous studies we could show that certain phenol- or
adamantyl-derivatives can increase peptide-loading of HLA-DR
molecules in a catalytic fashion [16,18]. As ‘MHC-loading
enhancer’ (MLE) they were able to act both on soluble as well
as on membrane-bound MHC molecules of HLA-DR transfected
fibroblast cells and EBV transformed B cells. However, with
regard to vaccination and immune therapy, the most important
antigen presenting cells are dendritic cells (DC). With short
catalytic dipeptides we have demonstrated that also these cells are
prone to induced ligand-exchange [19]. Given their potential as
additives for peptide vaccination we therefore investigated the
impact of organic MLE on DC. Adamantane ethanol (AdEtOH)
was used as MLE model compound throughout this study [16,18].
DC derived from the bone marrow of HLA-DR4-transgenic
mice were pulsed in the presence or absence of MLE with
biotinylated HA 306–318 peptide (HA), an epitope derived from
the hemagglutinin protein of the influenza virus [25]. The amount of
HA peptide bound to the surface of the cells was then determined
by flow cytometry, performing a double staining with HLA-DR
antibody and streptavidin conjugates. As shown in Fig. 1A, peptide
loading was indeed strongly enhanced when MLE were present
during pulsing. Compared to the control staining without any
peptide (left panel) the incubation with peptide alone revealed only
a marginal increase in peptide signal (middle panel). The presence
of MLE, in contrast, generated a very clear peptide-specific
staining particularly on the HLA-DR
bright cells. The signal of
bound peptide correlated directly with the HLA-DR4 expression
level of the cell, confirming the specificity of the loading reaction.
To assure that improved peptide loading by MLE directly
translates into an increased sensitivity of the antigen-specific T cell
response, the DC were used as APC in an in vitro T cell proliferation
assay to challenge two HA-specific CD4+ Tc e l lh y b r i d o m al i n e s
(Fig.1B).Asdepicted inFig.1B,bothfortheHLA-DR4(leftpanel)as
well as HLA-DR1 expressing DC (right panel), the threshold for T
cell activation could indeed be shifted by more than one order of
magnitude towards lower antigen concentrations. With peptide alone
the HLA-DR1 restricted EvHA T cells (right panel) responded only
weakly to DC incubated at concentrations below 100 ng/ml. The
addition of the MLE, however, resulted in the typical sigmoidal dose
response curve typically observed only at higher antigen concentra-
tion. This effect was even more pronounced for the HLA-DR4
restricted 8475/94 T cells which strongly proliferated in response to
antigen concentrations below 10 ng/ml when MLE was present
during peptide loading (right panel). Thus, MLE can significantly
improve the antigen-specific CD4+ Tc e l lr e s p o n s eb yi n c r e a s i n gt h e
amount of MHC II/antigen complexes on the cell surface of DC.
Selective enhancement of CD4+ T cell responses in vivo
by MLE
MLEbelongingtotheclassofadamantanederivatesareactiveon
all allelic variants of human MHC II molecule HLA-DR containing
the b86Gly residue [18] but not on murine MHC II. To explore the
in vivo activity of MLE during peptide vaccination we therefore
compared their effect in transgenic mice expressing the human
HLA-DR1 molecule, which is susceptible to adamantyl-mediated
catalysis, with BALB/c mice, expressing only MLE-insensitive
murine H2
d molecules. Both mouse strains, however, are known to
respond to HA 306–318 [26]. As shown in Fig.2B, BM-derived DC
from both mice can indeed be loaded with the peptide in a dose-
dependent fashion although HLA-DR1tg DC (right panel) seem to
present the antigen more efficient than BALB/c-derived DC (left
panel). Most importantly, however, strong enhancement of the
peptide loading reaction could be observed only for the cells
expressing the human HLA-DR1 molecule.
Based ontheseresults, the specificimpactofMLEonthe antigen-
specific CD4+ T cell response in vivo was determined in peptide
priming experiments. HLA-DR1 transgenic mice and BALB/c
were immunized subcutaneously with HA peptide dissolved in
‘IncompleteFreund’sAdjuvant’(IFA)supplementedbothwithCpG
as TLR-agonist and AdEtOH as MLE compound. Lymph node
cells were obtained twelve days later and restimulated in vitro in
presence of HA peptide. Antigen-specific IFNc production by
CD4+ T cells was assessed by intracellular flow cytometry staining
combined with anti-CD154 to identify activated antigen-specific
IFNc-secreting CD4+ cells [27] (Fig. 2B). BALB/c mice showed a
weak but specific response against the HA antigen (upper panels).
No difference in their frequency was observed whether MLE was
present during priming or not. Approximately, 0.02% of the CD4+
cells were detected IFNc+CD154+ in response to HA, while re-
stimulation with a control peptide did not induce any double
positive cells. In contrast, the fraction of antigen-specific T cells was
more than 4-fold increased in HLA-DR1 transgenic mice primed
with peptide/MLE compared to mice primed with peptide only
(lower panels). Hence, the result was in line with the anticipated
MLE-sensitivity of the two strains documented before in in vitro
loading experiments (compare Fig. 2A). Moreover, the apparent
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that at least under these experimental conditions the MLE vaccine
additives do not seem to trigger any unspecific T cell activation after
restimulation with an irrelevant peptide (Fig. 2B, right panels).
To further confirm the results obtained in vivo, IFNc secretion of
lymphocytes from primed mice was detected by Elispot assay
(Fig. 3). Also with this technique a strong increase in the total
number of spots, representing single IFNc producing cells, was
detected for HLA-DR1 mice when MLE were added during
vaccination (Fig. 3A). The use of larger cohorts of mice allowed us
to confirm the above results also statistically. A summary of the
data shows that a robust T cell response can be achieved in both
BALB/c and HLA-DR1 transgenic mice (Fig. 3B). Notably, only
in mice expressing the MLE-susceptible HLA-DR1 molecule a
significant increase (p=0.01) in the frequency of antigen-specific T
cells was evident when the priming was carried out in presence of
MLE (right panel). MLE had clearly no enhancing effect in MLE-
insensitive BALB/c. The average number of spots was even
slightly lower, albeit the difference was not significant (p=0.84).
Also no effect on INFc induction was detected after administration
of adjuvant supplemented with MLE alone (data not shown).
Thus, the effect is specific and on MLE-susceptible MHC II
directly translates into an improved T cell response in vivo.
MLE enhance the CD4+ T cell response against NY-ESO-1
epitopes
Multiple NY-ESO-1-derived epitopes have been reported
capable of provoking CD4+ T cell reponses [28–30]. As various
forms of cancer cells express NY-ESO-1, these epitopes may
therefore represent promising candidates for cancer vaccines.
Among those were NY-ESO-1 89–101, which can be presented
on HLA-DR1 [31], and the HLA-DR4-restricted NY-ESO-1 119–
143 epitope [28,32]. As both allelic HLA-DR variants are sensitive
to adamantyl-mediated ligand-exchange [16], we determined the
impact of AdEtOH on these tumour associated antigens (TAA) in
vitro, using HLA-DR transfected fibroblasts (Fig. 4A). Both epitopes
can be loaded onto the surface of cells expressing the relevant HLA-
DR molecules whereas no signal is observed in absence of the
human MHC class II molecules. Furthermore, adding MLE to the
loading procedure leads to a strong increase of NY-ESO-1 89-101
bound to HLA-DR1 (left panels) and to a lower extent also of NY-
ESO-1 119–143 bound to HLA-DR4 (right panels).
Figure 1. Influence of MLE on the class II MHC peptide-loading of dendritic cells. (A) Cell surface loading. HLA-DR4 expressing dendritic
cells (DC) generated from the bone marrow of HLA-DR4 transgenic mice were incubated for 4 h with medium alone (left panel) or with 5 mg/ml
biotinylated HA 306–318 peptide in the absence (middle panel) or presence of 250 mM AdEtOH, the model MLE compound used throughout this
study (right panel). Contour plots are shown for DC after staining with anti-HLA-DR antibody (R MHC expression) and streptavidin (R peptide load).
Mean peptide loading (MFI of streptavidin signal) is indicated. (B) CD4+ T cell response. DC from HLA-DR4tg mice (left panel) and from HLA-DR1tg
mice (right panel) were pulsed for 4 h with indicated amounts of HA 306–318 peptide in the absence (open circle) and presence (closed circle) of
250 mM AdEtOH. The cells were used to challenge HA 306–318 specific, HLA-DR4-restricted 8475/94 cells and HLA-DR1-restricted EvHA/X5 T cell
hybridoma cells, respectively. Background proliferation was measured in absence of peptide (dashed line).
doi:10.1371/journal.pone.0006811.g001
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DR transgenic mice were primed with the two NY-ESO-1
epitopes according to the protocol used before for the HA antigen.
As shown in Fig. 4B, the addition of MLE to the vaccine revealed
again a significant effect on the number of IFNc-secreting cells.
Based on the Elispot assay only 4 out of 13 HLA-DR1 transgenic
mice primed with NY-ESO-1 89–101 alone responded to the
peptide (left panel). In contrast 12 out of 13 mice reacted against
the antigen when MLE was added to the adjuvant and also the
average number of spots indicative for IFNc-secreting cells was
Figure 2. Selective enhancement of CD4+ T cell responses in vivo by MLE compounds. (A) Cell surface loading of MLE-susceptible and
–non-susceptible MHC molecules. DC generated from non-susceptible BALB/c mice (left panel) and AdEtOH-susceptible HLA-DR1tg (right panel)
were incubated for 4 h with the indicated amounts of biotinylated HA 306–318 peptide in the absence (open circles) or presence (closed circles) of
250 mM AdEtOH. Peptide loading was determined on CD11c+ cells by analyzing the mean fluorescence of the streptavidin-signal gated on a distinct
expression of HLA-DR. Background fluorescence was detected in the absence of biotinylated peptide (dashed line). (B) Peptide priming of mice.
BALB/c (upper panel) and DR1tg (lower panel) mice were s.c. primed with 100 mg and 3 mg HA 306–318, respectively in IFA/CpG supplemented
without (left panel) or with AdEtOH (middle panel). Specific T cell response was determined by intracellular flow cytometry staining at day 12 after
priming. Lymph node cells were incubated for 6 hrs in the presence of 10 mg HA 306–318 or 10 mg MOG 35–55 as irrelevant control peptide (right
panel) and aCD28 antibody. 3 mg/ml Brefeldin A was added for the last 2 h. Intracellular IFNc-production was analyzed on CD4+ CD154+ double
positive T cells. Numbers indicate frequency of CD4+ CD154+ IFNc+ cells among total CD4+ cells. Data representative of at least two independent
experiments are shown.
doi:10.1371/journal.pone.0006811.g002
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an Elispot assay. 12 days after vaccination, 1610
6 lymph node cells from mice primed with 3 mg HA 306–318 in IFA/CpG supplemented without (left
panel) or with AdEtOH (right panel) were incubated with titrated amounts of HA306–318 peptide on a plate coated with a-IFNc antibody. Detection
was carried out 48 hrs later by determining the spot number in each well. Spots represent single IFNc+ cells. (B) Statistical analysis of the T cell
response. Summarized Elispot data obtained from groups of BALB/c mice (left panel, n=10) and HLA-DR1tg mice (right panel, n=9) were analyzed
using student’s t test.
doi:10.1371/journal.pone.0006811.g003
Figure 4. MLE enhances the T cell response against NY-ESO-1 derived epitopes. (A) Cell surface loading of NY-ESO-1 epitopes. L929
fibroblasts transfected with HLA-DR1 (left panel) or HLA-DR4 (right panel) were incubated for 4 h with titrated amounts of NY-ESO-1 89–101 or NY-
ESO-1 119–143, respectively. Loading was performed in the absence (closed circles) or presence (open circles) of 250 mM AdEtOH. Non-transfected
L929 cells were used as a negative control (left side). Peptide loading was determined by analyzing the mean fluorescence of the streptavidin-signal
gated on a distinct expression of HLA-DR. Background fluorescence was detected in the absence of biotinylated peptide (dashed line). (B) Detection
of tumour-specific T cell response in vivo. Groups of HLA-DR1tg (left panel, n=13) or HLA-DR4tg (right panel, n=10) mice were s.c. primed with 5 mg
of the respective NY-ESO-1 epitopes in IFA/CpG supplemented with or without AdEtOH. 12 days after vaccination, 1610
6 Lymph node cells were
incubated with titrated amounts of NY-ESO-1 89–101 or NY-ESO-1 119–143, respectively. IFNc-detection was carried out 48 hrs later using an Elispot
assay and summarized data were analyzed using student’s t test.
doi:10.1371/journal.pone.0006811.g004
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DR4 transgenic mice primed with the NY-ESO-1 119–143
epitope (right panel) where in the presence of MLE a significant
boost of the antigen-specific priming was observed (p=0.027).
Enhancement of the immune response against NY-ESO-1
protein
Recombinant NY-ESO-1 is a medium sized protein with a
molecular weight of ,23 kD which has been used in multiple
clinical trials (http://clinicaltrials.gov). In a previous study we had
shown that MLE can also enhance the loading of larger protein
fragments onto MHC molecules [15]. We therefore tested whether
the effect of AdEtOH was evident also when using the
recombinant NY-ESO-1 protein. HLA-DR1 transgenic mice were
primed as described before, except that the recombinant protein
was used instead of peptide antigens. As shown in Fig. 5A, the
single cell analysis of lymph node cells challenged ex vivo with the
protein 12 days after priming revealed a similar picture as
Figure 5. MLE enhance the T cell response against NY-ESO-1 protein. (A) Determination of T cell response by intracellular cytokine staining. HLA-
DR1tgmiceweres.c.primedwith10 mgNY-ESO-1proteininIFA/CpGsupplementedwith(rightpanel)orwithoutAdEtOH(middlepanel).ThespecificTcell
response was determined by intracellular flow cytometry staining 12 days after priming. Lymph node cells were restimulated for 6 h in the presence of
10 mg NY-ESO-1 protein or control peptide (left panel) together with aCD28 antibody. 3 mg/ml Brefeldin A was added for the last 2 h. Intracellular IFNc-
production was analyzed on CD4+CD154+doublepositiveTcells.Numbersindicatefrequency ofCD4+CD154+ IFNc+ cellsamongtotalCD4+cells. Data is
representative of two independent experiments. (B) Dose-response. Groups of 5 mice were primed with 10 mg NY-ESO-1 protein emulsified in IFA/CpG
supplemented with(open circle) or withoutAdEtOH (closed circle). 12 daysafter vaccination1610
6 Lymph node cells were exvivo challenged withtitrated
amounts of NY-ESO-1 protein and IFNc-detection was carried out 48 hrs later using an Elispot assay. Spot numbers represent single IFNc+ cells.
doi:10.1371/journal.pone.0006811.g005
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IFNc+CD154+ CD4+ cells was increased when MLE was present
during the priming. The flow cytometry data was further
confirmed by a second series of experiments where the response
was analyzed in an IFNc-Elispot (Fig. 5B). In a dose-response
study the sensitivity of the NY-ESO-1 specific immune-response
increased by almost one order of magnitude. Thus, MLE may be
used as additive for both peptide- and protein-vaccines.
Discussion
So far, only two adjuvant components are regularly employed in
human vaccinations: mineral salts or oily emulsifiers as vehicles to
form an antigen depot and ‘immune-stimulants’, usually derived
from pathogen- or danger-associated compounds that act as
agonists for toll-like- (TLR) or other innate receptors [33]. In this
study we introduced with ‘MHC-loading enhancers’ (MLE)
another class of vaccine additive that improves CD4+ T cell
responses by mediating efficient antigen loading of the APC.
Surface MHC II molecules of APC are either blocked by high-
affine peptide-ligands or have acquired a non-receptive state [21].
MLE, such as adamantane ethanol (AdEtOH), are able to recover
non-receptive MHC II molecules and ‘open up’ free binding sites
by releasing ligands with lower affinity [15,16]. This allows to
significantly increase the number of antigen/MHC II complexes
on the cell surface of APC, shown here on BM-derived DC, where
the strong increase directly translated into a decreased concentra-
tion threshold required for T cell activation. In vivo, the addition of
MLE to the priming mixture resulted in a significantly higher
number of activated antigen-specific IFNc-secreting CD4+ T cells.
Also other types of CD4+ effector/memory cells such as Th2 or
Th17 cells can be affected in a similar way. In any case, the
increase in priming efficiency was specific and apparently based on
the interaction of the MLE with the MHC II molecule, since it was
evident only in mouse strains expressing MLE-susceptible HLA-
DR molecules.
Several classes of compounds have already been identified
exhibiting MLE activity. Besides organic structures such as
AdEtOH [18] or complex polycyclic compounds [17,34] also
simple aromatic chemicals like p-chlorophenol [15,16] short
peptide derivatives [19] and even certain solvents such as ethanol
and n-propanol [20] show the effect. Common to all of them is
that they act in a catalytic way independent of the antigen. They
can simply be added to the desired adjuvant and can be applied to
most of the common protocols used for vaccination.
Up to now, most of the tumour vaccines reported were targeting
mainly MHC class I. A number of recent studies confirmed,
however, that immunizations addressing CD4+ T cells are more
efficient than peptide vaccinations targeting only CD8+ cells
[35,36]. This may apply in particular also for tumour interventions.
Considering that tumour-associated T cell epitopes by definition
represent self-antigens, they have to be recognized by autoreactive
T cells. Their activation, however, is hindered by several safety
mechanisms ensuring that tolerance against self is maintained. They
are controlled by active suppressor mechanisms [37,38] and usually
expressonlyTCRwithalowaviditytotheirantigen[39].Successful
vaccination therefore needs to overcome tolerance mechanisms to
induce a powerful and sustained T cell response. At least in
autoimmune diseases the immune response is mostly driven by
autoreactive CD4+ T cell responses. Addressing them may
therefore be a key for the induction of successful anti-tumour
immune interventions, a process that could be aided by MLE.
As shown before [15] MLE catalyse not only the loading of
MHC molecules with small peptides, they can also mediate the
transfer of larger polypeptide fragments. In this study, a significant
enhancement was observed when AdEtOH was added to the
recombinant NY-ESO-1 protein used before in clinical trials.
While this may suggest its use in protein vaccines, its ability to
catalyse the loading of MHC with free protein fragments may also
impose a risk. MLE-mediated ligand exchange depends largely
only on the availability and we have shown that abundant
pathogenic autoantigens, such as multiple sclerosis-associated
myelin basic protein (MBP), can be transferred by this mechanism
onto MHC II [15]. In fact, Call et al. have shown that the
coapplication of encephalitogenic epitopes with chemical MLE-
compounds into HLA-DR2 transgenic mice leads to improved
peptide loading in vivo [34]. Our own studies further indicate, that
the presence of MLE increase the severity of experimental
autoimmune encephalomyelitis (EAE) triggered by this antigen
(Dickhaut et al., unpublished). Another drawback preventing
immediate applications may be the high concentration of MLE
used in this study. AdEtOH has to be regarded as a ‘first
generation compound’ and further studies are needed to identify
improved MLE and to determine their safety in preclinical trials.
As a ‘proof of concept’, however, we could show with AdEtOH as
an ‘MHC-loading enhancer’ prototype a promising new approach
to boost vaccination efficacy at the level of antigen-loading.
Methods
Peptides, reagents and antibodies
CpG OND 1826 (59-tccatgacgttcctgacgtt-39) was obtained from
(Biotez GmbH). Incomplete Freund’s adjuvant (IFA) was obtained
from Sigma. The following peptides were used: HA 306-318
(PKYVKQNTLKLAT), NY-ESO-1 89-101 (EFYLAMP-
FATPME), NY-ESO-1 119-143 (PGVLLKEFTVSGNILTIRL-
TAADHR) and MOG 35–55 (MEVGWYRSPFSRVVH-
LYRNGK). N-terminal biotinylation was introduced following
two 6-aminohexanoic acid spacer residues. Peptides were dissolved
in PBS at a stock solution of 1 mg/ml. Recombinant NY-ESO-1
protein was kindly provided by Dr. Gerd Ritter. MLE stocks were
kept as a 100 mM 2-(1-adamantyl)ethanol (Sigma) stock solution
dissolved in DMSO at 220uC. For flow cytometry staining the
following were used: a-CD4-PerCP-Cy5.5, a-CD11c-APC (both
from BD PharMingen) a-CD154-PE, a-IFNc-APC (both from
Miltenyi), a-HLA-DR-PE (BD Bioscience), a-CD86-Biotin (pro-
duced in our laboratory, clone GL1), streptavidin-APC (Caltag).
For Elispot assays the a-IFNc capture antibody (clone AN18.1724)
and the biotinylated a-IFNc detection antibody (clone R4-6A2)
were used, both produced from hybridoma supernatant in our
laboratory.
Animals
Mice were housed in the animal facility of the MDC under SPF
conditions and handled in accordance with the institutional
guidelines. Abb/HLA-DR4 (Taconic Farms, Denmark) and HLA-
DR1 [40] were bred at the MDC facility; BALB/c mice were
purchased from Charles River Laboratories (Sulzfeld, Germany)
and used at a age 8 to 15 weeks. Abb/HLA-DR4 mice were
generated in I-E 2/2 C57Bl/6, HLA-DR1tg mice are on a
B10M/J background. All animal experiments were approved by
the Landesamt fu ¨r Arbeitsschutz, Gesundheitsschutz und Tech-
nische Sicherheit (Berlin, Germany).
Cells
Cells weremaintained at 37uC in RPMI/5% FCS. The following
cells were used: L929 fibroblasts (ATCC) transfected with HLA-
DR1 (DRB1*0101) referred as L57.23 or HLA-DR4 (DRB1*0401)
MHC-Loading Enhancer In Vivo
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306–318 specific HLA-DR1-restricted mouse T cell hybridoma line
EvHA/X5 [18]. HA 306–318 specific HLA-DR4-restricted mouse
T cell hybridoma line 8475/94 (provided by L. Fugger). Dendritic
cells were generated from bone marrow of BALB/c and HLA-DR
transgenic mice according to published protocols [41] and cultured
in the presence of 10 ng/ml GM-CSF. Maturation was induced on
day seven of culture by adding 10 ng/ml LPS (Sigma) for 24 hrs.
Maturity was determined by expression of MHC class II and CD86
by flow cytometry analysis. Flow cytometry was performed on a
FACSCalibur or LSR II (both BD Bioscience), data was analysed
using CellQuest Software (BD Bioscience).
Peptide-loading of cell surface MHC molecules
Loading experiments were carried out as described [18]. Briefly,
1610
5 class II MHC expressing cells per well were incubated in a 96-
Well plate with the indicated amounts of biotinylated peptide at 37uC
in DMEM supplemented with 5% FCS. MLE were present during
the loading reaction at indicated concentrations. After 4 hrs cells
were washed and double stained with streptavidin-APC and a-HLA-
DR-PE (in PBS/2% FCS) for 20 min at 4uC before being washed
and analyzed on a Flow cytometer. Peptide loading was analyzed by
determining the SA-APCsignal on cells gated on a defined HLA-DR
expression. For loading experiments with BM-derived DC cells were
pregated on CD11c+ cells for further analysis.
T cell assay
T cell assays were carried out as described [18]. Briefly, 0,5–
1610
4 HLA-DR expressing DC per well were loaded with
indicated amounts of peptides at 37uC in absence or presence of
MLE. After 4 hrs cells were washed and 5610
4 HA specific
hybridome T cells were added to the culture for 24 hrs in 96 U-
bottom plates. T cell response was determined by measuring IL-2
production in a secondary assay using CTL-L cells (ATCC) as
described before [20].
Priming of mice
Mice were primed with indicated amounts of peptide or protein
in Incomplete Freund’s adjuvant (Sigma) supplemented with
50 mg CpG OND 1826 (Biotez GmbH). MLE were added to a
final concentration of 10 mM dissolved directly in Incomplete
Freund’s adjuvant. Mice were primed subcutaneously on the
flanks and neck, injecting a total volume of 200 ml. On day 12,
lymph nodes cells and spleens were harvested for ex vivo analysis.
Detection of ex vivo response by Elispot
1610
6 freshly isolated Lymph node cells per well were
incubated for 48 hrs (37uC, 5% CO2, RPMI 5% FCS) with
titrated amounts of peptide in Elispot plates (Multiscreen plates
HTS 96 well Filtration plate; Millipore) previously coated with a-
IFNc capture antibody (clone AN18.1724). Detection was carried
out according to the manufacturer’s recommendations, using
biotinylated a-IFNc detection antibody (clone R4-6A2) followed
by avidine–HRP enzyme conjugate (Sigma) and 3,3- diamino-
benzidine tablets (Sigma). Spots were counted using ‘Immuno-
Spot’ reader (C.T.L. Europe GmbH). Samples were set up in
duplicates and experiments were carried out at least twice.
Detection of ex vivo response by intracellular flow
cytometry staining
Briefly, 5610
5 lymph node cells per well were activated in the
presence of 10 mg/ml peptide and 2 mg/ml a-CD28 antibody
(produced in our laboratory, clone 37.51) for 6 hrs. Brefeldin
A (Sigma) was added for the final 2 hrs at a concentration of
3 mg/ml. Irrelevant peptide together with a-CD28 was used as a
negative control. After washing, cell surface was stained with a-
CD4 (PBS/2% FCS, 20 min, 4uC) followed by fixation and
permeabilization, using the Cytofix/Cytoperm
TM Kit (BD Biosci-
ence). Intracellular staining of CD154 and IFNc was carried out in
permeabilization buffer (PBS/2% FCS/0,5% saponin). Antigen-
specific cytokine production was assessed by determining the
frequency of CD154+ IFNc+ double positive cells among total
CD4+ lymphocytes.
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